Research Papers:

Overexpression of CHD1L is associated with poor survival and aggressive tumor biology in esophageal carcinoma

Ze-Han Liu, Qi Zhang, Yi-Jie Ding, Ying-Hui Ren, Hui-Peng Yang, Qing Xi, Ying-Nan Cheng, Guo-Lin Miao, Hong-Kun Liu, Cai-Xia Li, Wen-Qiang Yan, Yan Li, Zhenyi Xue, Lijuan Zhang, Xin-Ye Li, Chen-Long Zhao, Yurong Da, Xian-Zhong Wu, Jun-Qiang Chen _, Rongxin Zhang and Zhi-Gang Li

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:74178-74187. https://doi.org/10.18632/oncotarget.18830

Metrics: PDF 1266 views  |   HTML 2141 views  |   ?  


Ze-Han Liu1,*, Qi Zhang2,3,*, Yi-Jie Ding4,*, Ying-Hui Ren3, Hui-Peng Yang3, Qing Xi3, Ying-Nan Cheng3, Guo-Lin Miao3, Hong-Kun Liu3, Cai-Xia Li2, Wen-Qiang Yan5, Yan Li3, Zhenyi Xue3, Lijuan Zhang3, Xin-Ye Li6, Chen-Long Zhao6, Yurong Da3, Xian-Zhong Wu2, Jun-Qiang Chen7, Rongxin Zhang8,3 and Zhi-Gang Li9,6,2

1Nankai Clinical College, Tianjin Medical University, Tianjin, P.R. China

2Institute of Integrative Medicine Therapy for Acute Abdominal Diseases of Tianjin, Nankai Hospital, Tianjin, P. R. China

3Laboratory of Immunology and Inflammation, Department of Immunology, Key Laboratory of Immune Microenvironment and Diseases of Educational Ministry of China, Basic Medical College, Tianjin Medical University, Tianjin, P.R. China

4First Central Clinical College, Tianjin Medical University, Tianjin, P.R. China

5Department of Thoracic Surgery, Nankai Hospital, Nankai District, Tianjin, P. R. China

6General Hospital, Tianjin Medical University, Tianjin, P.R. China

7Department of Radiotherapy, Fujian Provincial Tumor Hospital, Affiliated Tumor Hospital of Fujian Medical University, Fuzhou, P.R. China

8Laboratory of Immunology and Inflammation, Guangdong Pharmaceutical University, Guangzhou, P.R. China

9Hainan Cancer Hospital, Affiliated Cancer Hospital of Hainan Medical College, Haikou City, P.R. China

*These authors have contributed equally to this work

Correspondence to:

Jun-Qiang Chen, email: [email protected]

Rongxin Zhang, email: [email protected], [email protected]

Zhi-Gang Li, email: [email protected]

Keywords: esophageal carcinoma, CHD1L protein, apoptosis, migration, prognosis

Received: March 21, 2017     Accepted: June 04, 2017     Published: June 29, 2017


Esophageal carcinoma (EC) is a malignancy with high metastatic potential. Chromosomal helicase/ATPase DNA binding protein 1-like (CHD1L) gene is a newly identified oncogene located at Chr1q21, and it is amplified in many solid tumors. However, the status of CHD1L protein expression in EC and its clinical significance is uncertain. This study was designed to investigate the significance of CHD1L expression in human EC and its biological function in EC cells. The expression of CHD1L was examined by immunohistochemistry in 191 surgically resected ECs. The associations between CHD1L expression and clinical pathological parameters and the prognostic value of CHD1L were analyzed. Western blot analysis showed that CHD1L was overexpressed in EC cell lines. In addition, positive CHD1L expression was strongly related to advanced clinical stage (P<0.01), and lymph node metastasis (P<0.01) of EC. The Kaplan-Meier curve indicated that high expression of CHD1L may result in poor prognosis of EC patients (P<0.01), and multivariate analysis showed that CHD1L overexpression was an independent predictor of overall survival. Furthermore, suppression of CHD1L in EC cells increased apoptosis and decreased cell proliferation invasion ability. Our results suggest that CHD1L is a target oncogene with the potential to serve as a novel prognostic biomarker in EC pathogenesis.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18830